Open AccessAntiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy
Author(s) -
Lı́dia Ruiz,
Eugènia Negredo,
Peré Domingo,
Roger Paredes,
Esther Francia,
Montserrat Balagué,
Sílvia Gel,
Anna Bonjoch,
Carmina R. Fumaz,
Susan S. Johnston,
Joan Romeu,
Joep M. A. Lange,
Bonaventura Clotet
Publication year - 2001
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200107010-00003
Subject(s) - lipodystrophy , nevirapine , medicine , protease inhibitor (pharmacology) , stavudine , viral load , gastroenterology , anthropometry , ritonavir , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy
Simpler and less toxic antiretroviral strategies are needed to maximize treatment compliance without sacrificing potency, at least for drug-experienced HIV-infected patients currently on regimens containing protease inhibitors (PIs). Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy.